Regenxbio says FDA places clinical hold on RGX-121
Regenxbio says the FDA places a clinical hold on RGX-121 after spine MRI findings and does not expect to resubmit the RGX-121 BLA in the near term.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.